Accession Number: | 0001449374-19-000015 |
Date: | 2019-04-18 |
Issuer: | CAS MEDICAL SYSTEMS INC (CASM) |
Original Submission Date: |
MILINAZZO ALAN
C/O CAS MEDICAL SYSTEMS, INC.
44 EAST INDUSTRIAL ROAD
BRANFORD, CT 06405
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2019-04-18 | D | 42,500 | d | $2.45 | 0 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION | 1.26 | 2019-04-18 | deemed execution date | D | 30,000 (d) | 2025-06-23 | common stock 30,000 | $1.26 | 0 | direct | ||
STOCK OPTION | 1.64 | 2019-04-18 | deemed execution date | D | 15,000 (d) | 2025-12-17 | common stock 15,000 | $1.64 | 0 | direct |
ID | footnote |
---|---|
f1 | each issued and outstanding share of common stock was, as a result of the consummation of the merger contemplated by the agreement and merger by and among cas medical systems, inc., edwards lifesciences holding, inc. and crown merger sub, inc., dated as of february 11, 2019 (the "merger agreement"), canceled in exchange for the right to receive a per share amount equal to $2.45 in cash without interest. |
f2 | this option, which vested in four equal annual installments commencing on june 23, 2016, was, as a result of the consummation of the merger contemplated by the merger agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option. |
f3 | this option, which vested in two equal annual installments commencing on december 17, 2016, was, as a result of the consummation of the merger contemplated by the merger agreement, canceled in exchange for a cash payment equal to the product of the number of shares subject to such option multiplied by the excess of $2.45 over the exercise price per share of such option. |